Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

BACKGROUND: Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients with advanced cancer harboring the KRAS G12C mutation. METHODS: Eligible patients (aged ≥18 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Judy, Martin-Romano, Patricia, Cassier, Philippe, Johnson, Melissa, Haura, Eric, Lenox, Laurie, Guo, Yue, Bandyopadhyay, Nibedita, Russell, Michael, Shearin, Elizabeth, Lauring, Josh, Dahan, Laetitia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255981/
https://www.ncbi.nlm.nih.gov/pubmed/35325211
http://dx.doi.org/10.1093/oncolo/oyab080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255981/
https://www.ncbi.nlm.nih.gov/pubmed/35325211
http://dx.doi.org/10.1093/oncolo/oyab080

Ejemplares similares